Taiwan
· Delayed Price · Currency is TWD Oneness Biotech Statistics
Total Valuation
Oneness Biotech has a market cap or net worth of TWD 49.42 billion. The enterprise value is 43.12 billion.
| Market Cap | 49.42B |
| Enterprise Value | 43.12B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Oneness Biotech has 477.46 million shares outstanding. The number of shares has increased by 1.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 477.46M |
| Shares Change (YoY) | +1.40% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 7.82% |
| Owned by Institutions (%) | 5.88% |
| Float | 314.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -34.26 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -103.79 |
Financial Position
The company has a current ratio of 39.99, with a Debt / Equity ratio of 0.03.
| Current Ratio | 39.99 |
| Quick Ratio | 39.02 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.99 |
| Interest Coverage | -119.47 |
Financial Efficiency
Return on equity (ROE) is -9.08% and return on invested capital (ROIC) is -4.93%.
| Return on Equity (ROE) | -9.08% |
| Return on Assets (ROA) | -4.80% |
| Return on Capital (ROIC) | -4.93% |
| Revenue Per Employee | 2.61M |
| Profits Per Employee | -29.27M |
| Employee Count | 43 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -45.84% |
| 50-Day Moving Average | 132.53 |
| 200-Day Moving Average | 149.39 |
| Relative Strength Index (RSI) | 25.87 |
| Average Volume (20 Days) | 3,217,367 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oneness Biotech had revenue of TWD 112.20 million and -1.26 billion in losses. Loss per share was -2.64.
| Revenue | 112.20M |
| Gross Profit | 63.08M |
| Operating Income | -1.14B |
| Pretax Income | -1.28B |
| Net Income | -1.26B |
| EBITDA | -695.33M |
| EBIT | -1.14B |
| Loss Per Share | -2.64 |
Balance Sheet
The company has 7.17 billion in cash and 411.91 million in debt, giving a net cash position of 6.76 billion or 14.15 per share.
| Cash & Cash Equivalents | 7.17B |
| Total Debt | 411.91M |
| Net Cash | 6.76B |
| Net Cash Per Share | 14.15 |
| Equity (Book Value) | 13.53B |
| Book Value Per Share | 27.38 |
| Working Capital | 7.26B |
Cash Flow
In the last 12 months, operating cash flow was -349.58 million and capital expenditures -65.86 million, giving a free cash flow of -415.44 million.
| Operating Cash Flow | -349.58M |
| Capital Expenditures | -65.86M |
| Free Cash Flow | -415.44M |
| FCF Per Share | -0.87 |
Margins
| Gross Margin | 56.22% |
| Operating Margin | -1,013.80% |
| Pretax Margin | -1,138.14% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -370.28% |
Dividends & Yields
Oneness Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -1.40% |
| Shareholder Yield | -1.40% |
| Earnings Yield | -2.55% |
| FCF Yield | -0.84% |
Stock Splits
The last stock split was on July 26, 2024. It was a forward split with a ratio of 1.049967976.
| Last Split Date | Jul 26, 2024 |
| Split Type | Forward |
| Split Ratio | 1.049967976 |
Scores
Oneness Biotech has an Altman Z-Score of 58.15.
| Altman Z-Score | 58.15 |
| Piotroski F-Score | n/a |